Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the LiteratureBerm, E. J. J., Looff, M. D., Wilffert, B., Boersma, C., Annemans, L., Vegter, S., van Boven, J. FM. & Postma, M. J., 11-Jan-2016, In : PLoS ONE. 11, 1, 22 p., e0146262.
Research output: Contribution to journal › Article › Academic › peer-review
- Pharmacotherapy and Pharmaceutical Care
- Methods in Medicines evaluation & Outcomes research (M2O)
- Reproductive Origins of Adult Health and Disease (ROAHD)
- Pharmacoepidemiology and Pharmacoeconomics
- Microbes in Health and Disease (MHD)
- PharmacoTherapy, Epidemiology and Economics
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Value, Affordability and Sustainability (VALUE)
- Groningen Research Institute for Asthma and COPD (GRIAC)
Due to extended application of pharmacogenetic and pharmacogenomic screening (PGx) tests it is important to assess whether they provide good value for money. This review provides an update of the literature.
A literature search was performed in PubMed and papers published between August 2010 and September 2014, investigating the cost-effectiveness of PGx screening tests, were included. Papers from 2000 until July 2010 were included via two previous systematic reviews. Studies' overall quality was assessed with the Quality of Health Economic Studies (QHES) instrument.
We found 38 studies, which combined with the previous 42 studies resulted in a total of 80 included studies. An average QHES score of 76 was found. Since 2010, more studies were funded by pharmaceutical companies. Most recent studies performed cost-utility analysis, univariate and probabilistic sensitivity analyses, and discussed limitations of their economic evaluations. Most studies indicated favorable cost-effectiveness. Majority of evaluations did not provide information regarding the intrinsic value of the PGx test. There were considerable differences in the costs for PGx testing. Reporting of the direction and magnitude of bias on the cost-effectiveness estimates as well as motivation for the chosen economic model and perspective were frequently missing.
Application of PGx tests was mostly found to be a cost-effective or cost-saving strategy. We found that only the minority of recent pharmacoeconomic evaluations assessed the intrinsic value of the PGx tests. There was an increase in the number of studies and in the reporting of quality associated characteristics. To improve future evaluations, scenario analysis including a broad range of PGx tests costs and equal costs of comparator drugs to assess the intrinsic value of the PGx tests, are recommended. In addition, robust clinical evidence regarding PGx tests' efficacy remains of utmost importance.
|Number of pages||22|
|Publication status||Published - 11-Jan-2016|
- COST-EFFECTIVENESS ANALYSIS, METASTATIC COLORECTAL-CANCER, ACUTE CORONARY SYNDROME, INFLAMMATORY-BOWEL-DISEASE, POLYMERASE-CHAIN-REACTION, HIV-INFECTED PATIENTS, STAGE BREAST-CANCER, CHRONIC HEPATITIS-C, CELL LUNG-CANCER, PERSONALIZED MEDICINE